Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesaglitazar Lipid Effects in T2D with Low HDL
NCT00261352Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of tesaglitazar in type 2 diabetes mellitus (T2DM) and dyslipidemia (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in High-Density Lipoprotein Cholesterol at 24 weeks. Started Mar 2005; status: terminated.
02
Drugs
tesaglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NCT00261352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261352.